glp 1 and cannabis Glucagon-like peptide-1 medicines in neurological psychiatric disorders Are GLP-1 drugs turning down

Increased risk of low blood sugar in people with type 2 diabetes mellitus who also take medicines to treat their diabetes (such as insulin or sulfonylureas)

Hybrid care models integrating pharmacotherapy with lifestyle support show promise for sustainable outcomes ( 3.2 Divergent muscle outcomes in weight loss interventions

In the follow-up of ET cycles for patients, it was found that 5 patients (10.6%) in the l-carnitine group and 3 patients (6%) in the control group have not referred for FET cycles until the time of data analysis ( P = 0.65)

The mechanistic target of rapamycin (mTOR) signaling is a key modulator of anabolic and catabolic reactions 34 , which in turn could affect ROS balance